I3Y-MC-JPCS - ClinicalTrials.gov - NCT04238819
I3Y-MC-JPCS - ClinicalTrials.gov - NCT04238819
Key Requirements
Key Requirements
Use the following checklist to help determine if this trial may be a good fit for you. Place a checkmark next to each criteria that you successfully meet.
Participants must
Participants must have body weight ≥10 kg and BSA ≥ 0.5 m2
Participants must have diagnosis of relapsed/refractory solid tumor
Participants must have discontinued all previous treatments for cancer
Participants must have a life expectancy of at least 8 weeks
Participants must NOT
Participants must not have received a bone marrow or organ transplant
Participants must not have received a live vaccination within 4 weeks of starting the study
Participants must not be pregnant or breastfeeding
Participants must not have a personal history of specific illnesses such as certain cardiovascular disorders, severe renal impairment, interstitial lung disease, and certain gastrointestinal disorders
Participants must not have active systemic infections or viral loads
Participants must not have diagnosed and/or treated additional malignancy within 3 years prior to enrollment (with some exceptions)
Trial Summary
Conditions the trial is for
Solid Tumor, Pediatric Solid Tumors, Pediatric Cancer
What the trial is testing?
Abemaciclib, Irinotecan, Temozolomide
Could I receive a Placebo?
no
Enrollment Goal
60
Trial Dates
November 2020 - January 2023
Trial Phase
1
Key Requirements
Use the following checklist to help determine if this trial may be a good fit for you. Place a checkmark next to each criteria that you successfully meet.
Participants must
Participants must have body weight ≥10 kg and BSA ≥ 0.5 m2
Participants must have diagnosis of relapsed/refractory solid tumor
Participants must have discontinued all previous treatments for cancer
Participants must have a life expectancy of at least 8 weeks
Participants must NOT
Participants must not have received a bone marrow or organ transplant
Participants must not have received a live vaccination within 4 weeks of starting the study
Participants must not be pregnant or breastfeeding
Participants must not have a personal history of specific illnesses such as certain cardiovascular disorders, severe renal impairment, interstitial lung disease, and certain gastrointestinal disorders
Participants must not have active systemic infections or viral loads
Participants must not have diagnosed and/or treated additional malignancy within 3 years prior to enrollment (with some exceptions)
Trial Summary
Conditions the trial is for
Solid Tumor, Pediatric Solid Tumors, Pediatric Cancer
What the trial is testing?
Abemaciclib, Irinotecan, Temozolomide
Could I receive a Placebo?
no
Enrollment Goal
60
Trial Dates
November 2020 - January 2023
Trial Phase
1
Trial Locations
Hide locations not currently recruiting